The asthma market consists of many well-established therapies, including inhaled agents (e.g., GlaxoSmithKline’s Advair/Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim’s Spiriva), oral drugs (e.g., montelukast), and biologics (e.g., Roche/Novartis’s Xolair, GlaxoSmithKline’s Nucala). However, market dynamics are evolving as branded-generic and generic alternatives to inhaled blockbuster agents continue to launch and new biologics targeting niche populations within the severe asthma segment are approved. These events have increased—and will continue to increase—competition in this lucrative market. With the impending entry of additional biological therapies, the launch of branded-generic and generic inhaled drugs in new markets, and the potential launch of LABA/LAMA/ICS combination agents, the asthma market is poised to experience change over the next decade.
- What are KOLs’ insights on current inhaled branded, branded-generic, and generic treatment options?
- What is/will be the market impact of branded-generic and generic inhaled therapies?
- What are KOLs’ perceptions of the currently marketed asthma biologics (Xolair, Nucala, Teva’s Cinqair/Cinqaero, AstraZeneca’s Fasenra)?
- Where in the treatment algorithm do physicians fit these drugs?
- What drives physicians’ choice of a biologic in severe refractory asthma patients?
- How will the market evolve over the next ten years given the launch of additional inhaled, oral, and biological products?
- Will the entry of triple LABA/LAMA/ICS combination agents have a substantial effect on the sales and patient share of currently marketed asthma therapies?
- Where do physicians see these triple therapies fitting in the treatment algorithm?
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
39 country-specific interviews with thought leaders.
Number of diagnosed and drug-treated prevalent cases of asthma; number of diagnosed and drug-treated prevalent cases of intermittent/mild persistent and moderate/severe persistent asthma.
Preregistered: 1 drug; Phase III: 8 drugs; Phase II: 11 drugs; coverage of 2 select preclinical/Phase I product